Mulakan
ReutersReuters

FDA Grants Platform Tech Designation To Viral Vector In Sarepta's SRP-9003 For LGMD Type 2E/R4

RefinitivBacaan kurang dari 1 minit
SRPT

Sarepta Therapeutics Inc SRPT:

  • U.S. FDA GRANTS PLATFORM TECHNOLOGY DESIGNATION TO THE VIRAL VECTOR USED IN SRP-9003, SAREPTA’S INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2E/R4

ReutersSaham AS
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini

Lebih berita dari Reuters